Grifols Management

Management Kriterienprüfungen 2/4

Grifols' CEO ist Nacho Abia Buenache , ernannt in Apr 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.014% der Aktien des Unternehmens, im Wert von €720.90K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.4 Jahre bzw. 8.6 Jahre.

Wichtige Informationen

Nacho Abia Buenache

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	6.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.6yrs

Jüngste Management Updates

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

May 18

Is Grifols (BME:GRF) Using Too Much Debt?

Apr 30

Geschäftsführer

Nacho Abia Buenache (56 yo)

less than a year

Amtszeit

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thomas Glanzmann	Executive Chairman	18.2yrs	€1.90m	0.029% € 1.4m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	keine Daten	0.014% € 654.2k
Alfredo Guerra	CFO & VP	17.4yrs	keine Daten	keine Daten
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	keine Daten	keine Daten
Nuria Lapeña	VP of Corporate Treasury	no data	keine Daten	keine Daten
David Bell	Chief Corporate Development	21.4yrs	keine Daten	0.0029% € 141.2k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.4yrs	keine Daten	0.00078% € 37.3k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	keine Daten	keine Daten
Vicente Blanquer Torre	Chief Quality Officer	31.4yrs	keine Daten	0.0066% € 315.4k
Sergio Adell	President of Commercial Tech Support	5.4yrs	keine Daten	keine Daten
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 759.9k
Miguel Montblanch	President of Commercial Operations Support	12.4yrs	keine Daten	keine Daten

6.4yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrenes Management: GRFDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thomas Glanzmann	Executive Chairman	18.2yrs	€1.90m	0.029% € 1.4m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	keine Daten	0.014% € 654.2k
Víctor Grifols Deu	Executive Director	8.1yrs	€1.04m	0.016% € 759.9k
Juan Twose Roura	Member of the Advisory Committee	9.4yrs	€380.00k	keine Daten
Raimon Grifols Roura	Vice-Chairman	9.1yrs	€1.04m	0.0060% € 289.5k
Tomas Daga Gelabert	Independent External Director	24.2yrs	keine Daten	0.045% € 2.1m
Inigo Mardones	Independent Director	9.1yrs	€150.00k	keine Daten
Carina Szpilka Lázaro	Lead Independent Director	9.1yrs	€150.00k	0.00022% € 10.5k
Albert Coma-Cros	Proprietary Director	less than a year	keine Daten	0.0097% € 465.1k
Enriqueta Font	Independent Director	5.1yrs	€125.00k	keine Daten
Montserrat Abellana	Independent Director	2yrs	€63.00k	keine Daten
Susana Gonzalez Rodriguez	Independent Director	2yrs	€63.00k	keine Daten

8.6yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: GRFDie Vorstandsmitglieder gelten als erfahren (8.6 Jahre durchschnittliche Amtszeit).

Grifols Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Consensus EPS estimates fall by 12%

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Consensus EPS estimates fall by 54%

Investor sentiment improves as stock rises 19%

Is Grifols (BME:GRF) Using Too Much Debt?

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter